Want to join the conversation?
$AMGN said FDA approved Amjevita (adalimumab-atto) for the treatment of seven inflammatory diseases. This includes moderate-to-severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic plaque psoriasis, Crohn's disease and ulcerative colitis.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.